Lamivudine
Back to searchMolecule Structure
Scientific Name
Lamivudine
Description of the Drug
Lamivudine is a reverse transcriptase inhibitor used to treat HIV and hepatitis B infections.
Source: DrugBank Online – DrugBank.com. Retrieved 2023-02-07 from
http://www.drugbank.ca/drugs/DB00709
http://www.drugbank.ca/drugs/DB00709
Brand Name(s)
Epivir, Epivir-hbv, Lamivudine, Zeffix
Company Owner(s)
Lannett Co Inc, Celltrion Inc, Apotex Inc, Lupin Ltd, Merck Sharp And Dohme Corp, Zydus Pharmaceuticals Usa Inc, Annora Pharma Private Ltd, Anda Repository Llc, Mylan Pharmaceuticals Inc, Hetero Labs Ltd Unit V
Mechanism(s) Of Action
| Target Name | Target Type | Action Type | Target ChEMBL ID |
|---|---|---|---|
| DNA polymerase/reverse transcriptase | SINGLE PROTEIN | INHIBITOR | CHEMBL2362994 |
| DNA | NUCLEIC-ACID | INHIBITOR | CHEMBL2363046 |
| DNA | NUCLEIC-ACID | INHIBITOR | CHEMBL2363047 |
| Human immunodeficiency virus type 1 reverse transcriptase | SINGLE PROTEIN | INHIBITOR | CHEMBL247 |
| DNA | NUCLEIC-ACID | INHIBITOR | CHEMBL2363048 |
Clinical Trial(s)
Unichem Links
| SureChEMBL | SCHEMBL109675 | ||||
| PharmGKB | PA450163 | ||||
| Human Metabolome Database | HMDB0014847 | ||||
| WDI | GR109714X | ||||
| DrugBank | DB00709 | ||||
| PubChem: Thomson Pharma | 14798125 | 15121620 | |||
| PubChem | 60825 | ||||
| Mcule | MCULE-8483986532 | MCULE-2096184994 | |||
| LINCS | LSM-5215 | ||||
| Nikkaji | J457.051K | ||||
| PDBe | 3TC | ||||
| BindingDB | 50366817 | ||||
| DrugCentral | 1539 | ||||
| Brenda | 229604 | 4247 | 228663 | 229605 | 6246 |
| ChemicalBook | CB1290608 | ||||
| GSRS | 75aef525-0768-4d1f-9548-6589da8cfdcb | ||||
| rxnorm | LAMIVUDINE | EPIVIR | |||
| PubChem: Drugs of the Future | 12014700 | ||||
| KEGG Ligand | C07065 | ||||
| ChEBI | 63577 | ||||
| NIH Clinical Collection | SAM002589994 | SAM001246582 | |||
| ZINC | ZINC000000012346 |
